Table 2.
Summary data on associations between ERCC1 polymorphisms and ORR, OS, and PFS of platinum-based chemotherapy in NSCLC.
| Study (cases) | Total | Study (cases) | Asian | Study (cases) | Caucasian | |
|---|---|---|---|---|---|---|
| ERCC1 C118T | ||||||
| ORR | ||||||
| CT + TT versus CC | 23 (3272) | 0.82 [0.71, 0.96] | 14 (2361) | 0.80 [0.67, 0.94] | 9 (911) | 0.93 [0.66, 1.30] |
| I 2 = 48.9%, P heterogeneity = 0.005 | I 2 = 61.9%, P heterogeneity = 0.001 | I 2 = 5.6%, P heterogeneity = 0.389 | ||||
| CT versus CC | 16 (2023) | 0.73 [0.61, 0.89] | 9 (1499) | 0.69 [0.55, 0.85] | 7 (524) | 0.93 [0.62, 1.38] |
| I 2 = 9%, P heterogeneity = 0.35 | I 2 = 0%, P heterogeneity = 0.44 | I 2 = 16%, P heterogeneity = 0.31 | ||||
| TT versus CC | 16 (1314) | 0.63 [0.47, 0.85] | 9 (985) | 0.64 [0.44, 0.93] | 7 (329) | 0.63 [0.39, 1.01] |
| I 2 = 19%, P heterogeneity = 0.24 | I 2 = 20%, P heterogeneity = 0.27 | I 2 = 30%, P heterogeneity = 0.20 | ||||
| OS | ||||||
| CT + TT versus CC | 16 (2734) | 1.25 [1.05, 1.50] | 8 (1949) | 1.24 [1.01, 1.53] | 8 (785) | 1.27 [0.88, 1.85] |
| I 2 = 69.2%, P heterogeneity = 0.000 | I 2 = 79.2%, P heterogeneity = 0.000 | I 2 = 53.4%, P heterogeneity = 0.036 | ||||
| CT versus CC | 5 (1276) | 1.09 [0.86, 1.38] | 5 (1276) | 1.09 [0.86, 1.38] | 0 | |
| I 2 = 50%, P heterogeneity = 0.09 | I 2 = 50%, P heterogeneity = 0.09 | |||||
| TT versus CC | 5 (1276) | 1.49 [1.18, 1.88] | 5 (1276) | 1.49 [1.18, 1.88] | 0 | |
| I 2 = 48%, P heterogeneity = 0.11 | I 2 = 48%, P heterogeneity = 0.11 | |||||
| PFS | ||||||
| CT + TT versus CC | 9 (943) | 1.11 [0.84, 1.47] | 3 (367) | 1.15 [0.86, 1.54] | 6 (576) | 1.06 [0.64, 1.75] |
| I 2 = 61.2%, P heterogeneity = 0.008 | I 2 = 50.4%, P heterogeneity = 0.133 | I 2 = 69.7%, P heterogeneity = 0.006 | ||||
| CT versus CC | 1 (137) | 1.47 [0.91, 2.36] | 1 (137) | 1.47 [0.91, 2.36] | 0 | |
| TT versus CC | 1 (137) | 1.86 [1.13, 3.07] | 1 (137) | 1.86 [1.13, 3.07] | 0 | |
| ERCC1C8092A | ||||||
| ORR | ||||||
| CA + AA versus CC | 11 (1607) | 0.87 [0.71, 1.07] | 8 (1279) | 0.76 [0.60, 0.96] | 3 (328) | 1.51 [0.95, 2.39] |
| I 2 = 56.1%, P heterogeneity = 0.012 | I 2 = 56.1%, P heterogeneity = 0.025 | I 2 = 0%, P heterogeneity = 0.967 | ||||
| CA versus CC | 6 (793) | 0.71 [0.53, 0.96] | 6 (793) | 0.71 [0.53, 0.96] | 0 | |
| I 2 = 57%, P heterogeneity = 0.04 | I 2 = 57%, P heterogeneity = 0.04 | |||||
| AA versus CC | 6 (529) | 0.42 [0.26, 0.70] | 6 (529) | 0.42 [0.26, 0.70] | 0 | |
| I 2 = 0%, P heterogeneity = 0.57 | I 2 = 0%, P heterogeneity = 0.57 | |||||
| OS | ||||||
| CA + AA versus CC | 5 (824) | 1.18 [0.77, 1.79] | 4 (705) | 1.37 [1.06, 1.75] | 1 (119) | 0.50 [0.33, 0.84] |
| I 2 = 77.6%, P heterogeneity = 0.001 | I 2 = 26.4%, P heterogeneity = 0.253 | |||||
| CA versus CC | 4 (569) | 1.38 [1.03, 1.86] | 4 (569) | 1.38 [1.03, 1.86] | 0 | |
| I 2 = 0%, P heterogeneity = 0.41 | I 2 = 0%, P heterogeneity = 0.41 | |||||
| AA versus CC | 4 (569) | 2.03 [1.19, 3.47] | 4 (569) | 2.03 [1.19, 3.47] | 0 | |
| I 2 = 54%, P heterogeneity = 0.09 | I 2 = 54%, P heterogeneity = 0.09 | |||||
| PFS | ||||||
| CA + AA versus CC | 1 (90) | 1.08 [0.72, 1.63] | 1 (90) | 1.08 [0.72, 1.63] |